Viking Therapeutics Inc (VKTX) Quote

You are using - Short-term investments – available-for-sale - that doesn't mean Viking has $900 million in cash on Hand.

The cash and Cash equivalents isn't close to $900.

Deflectors on maximum. They have $900 million in cash and short term investments that can be used to fund the ~$300 million needed for the phase 3 trials. Do you understand what short term investments means? By the way, VKTX won't be spending $300 million on day 1. It will be spread out over 1-2 years. Given the long time frames, that is essentially the same as having cash.

I looked over you posting history. You are an uninformed short whose comments over a wide range of stocks are meaningless. This is just the latest example.

Here is the link for when VKTX raised over $600 million in cash in March of 2024.

https://ir.vikingtherapeutics.com/2024-03-04-Viking-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares

I don't believe you know how to read a financial statement.

You are using - Short-term investments – available-for-sale - that doesn't mean Viking has $900 million in cash on Hand.

The cash and Cash equivalents isn't close to $900.

You might want to look at all of the S-8 which is to register stock to be given to employees as part of a benefit plan. This is dilutive to retail investors.

We already know the insiders are dumping stock.

"Brian Lian - President & CEO of Viking Therapeutics Inc, executed a sale of 35,000 shares in the company on January 30, 2024, according to a recent SEC Filing.

Over the past year, the insider has sold a cumulative total of 349,336 shares of Viking Therapeutics Inc and has not made any purchases of the stock. The company's insider transaction history indicates a pattern of sales with 15 insider sells and no insider buys over the same timeframe.

The transaction was carried out at an average price of $23.95 per share, which resulted in a total value of $837,250. Following this transaction, the insider's stake in Viking Therapeutics Inc has been adjusted as per the latest filings."

IG

Some folks DD is lazy, thanks for setting this $$ record straight!

Where is the capital for the $300 million for Phase 3 clinical trials?

What?? If you have done even the barest minimum of research on VKTX you would know they have over $900 million in cash on hand.

VKTX 2Q24 CC notes by ‘Mufaso’:

#msg-174812392

Where is the capital for the $300 million for Phase 3 clinical trials?

Why hasn't the company posted any of the results from from past studies.

"Results Overview
No Study Results Posted on ClinicalTrials.gov for this Study"

IG

I bet this fine company will be bought out in the next 12months. 👍💰👍💰

$vltx $67's apparently the market likes the news

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
https://seekingalpha.com/article/4706587-viking-therapeutics-better-than-expected-trial-timelines-while-pipeline-expands?mailingid=36182871&messageid=2800&serial=36182871.2121&source=email_2800&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=36182871.2121

TY However, the design of the VK2735 phase-3 trials will not be finalized until after the end-of-phase-2 meeting with the FDA in 2H24, which more than likely means 4Q24.

Viking sends Lilly, Novo lower as obesity drug enters late-stage program

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174804489

$VKTX 62 nhod

$vktx 56 break! $VKTX up 10%+ in AH on a surprise move to Phase 3 trials.

Maybe the best weight loss drug on the planet...and it's Oral vs. Injections for the big winners so far.

Reminder - they did a huge raise at $85 and the stock is currently at $55.

Expecting EPIC call buying tomorrow. https://t.co/LpQIgcoldk— Commodities MacGruber (@GoForGrubes2) July 24, 2024

In since $3.50 sold initial investment at 87.00 riding the houses $

$VKTX

VKTX 10Q due 4/24
Next day settlement begins 5/28

I bet an ELI or NOVO buyout is soon.

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

What a crazy couple of weeks……

Time to jump back in from these levels ??

I think so.

$$ VKTX $$

$VKTX $70'S FROM 79

$vktx $VKTX Truist PT 120

Raymond James PT 115

Irrational selloff

Recall $MDGL irrational selloff I was beating the drum when shares dropped to $168 or so after early data $LLY reported data for MASH

In just few weeks $MDGL actually went higher from selloff pivot point

A $100+…— Pharmdca (@Pharmdca) March 8, 2024

Another marvelous day, fellow Vikings.

Let’s get over $100 already, lol.

$$ VKTX $$

It doesn’t have to own a plant, but it does need a plant that will make its pipeline of molecules better than the Indiana plant of CTLT (NOVO NORDISK) that just got slapped with a warning letter from FDA. I suggested CDMO whose reactor plants have always been FDA approved for good manufacturing methods. Avid Bioservices (CDMO) has supplied raw material to HALO for years to make its Enhanze delivery system for molecules e.g., JNJ’s Darzalex.

Why does VKTX need a proprietary delivery system?

Are you aware of LEXX? Said to have a delivery system for molecules like VKTX has that will turn both into a blockbuster.

I understand that VKTX has no facilities with reactors capable of making its pipeline of molecules. CDMO has an expanded capacity plant up the coast from San Diego in Tustin, and a wholly new plant further up the coast near John Wayne airport. GILD has plants in Forest City, and JNJ has plants in South San Francisco. What do you hear on the topic?

Buying opportunity, imho……

$80 call options look really good to me at this time, imho.

Go Viking!

VKTX sells—(upsized)—7.44M* shares@ $85.00—essentially_no_discount_to_Tuesday’s_closing_price:

https://www.prnewswire.com/news-releases/viking-therapeutics-announces-pricing-of-550-million-public-offering-of-common-stock-302074989.html

Net proceeds will be ~$595M* after underwriting fees.

*Assuming exercising of underwriter’s option.

Another great day…….lets bust through $100 this week.

Oppenheimer adjusts their VKTX price target to $116…….maintains outperform rating.

$$ VKTX $$

If I had this stock at .08, I would be selling.

Didn't ask for much money. This stock will continue to rise.

$1,260,000,000 billion in debt.You need a better pair of glasses—this is VKTX’s 12/31/23 balance sheet:

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/0001607678/000095017024012322/vktx-20231231.htm#balance_sheets

GILD is providing at least $12 miliion in grant money over 3 years to scores of institutions, states and cities scattered around the country to help women and transgenders to combat HIV. Will this program make Biktarvy available, or will it make VKTX oral/injectable med available, or both. The bigger question is whether GILD will use its remaining cash $$$ to acquire/merge with VKTX, IMO.

Viking Therapeutics proposes $350M stock offering after shares more than double in value

https://www.msn.com/en-us/money/markets/viking-therapeutics-proposes-350m-stock-offering-after-shares-more-than-double-in-value/ar-BB1j0cVc#:~:text=Viking%20Therapeutics%20%28NASDAQ%3AVKTX%29%20on%20Tuesday%20announced%20a%20proposed,trading%20following%20positive%20results%20from%20a%20mid-stage%20trial.

Your debt number is high by a factor of 1,000 and they have hundreds of millions in cash enough for a dozen quarters. And the new offering will double that cash and give them enough cash to make it to market, if they choose.

It's 1.26 million, not billion in debt.

VKTX: And the REAL REASON for this unusual run-up!!! (Brilliantly articulated in the below article!!!)

"MW Viking Therapeutics stock almost doubles as investors cheer cheap entry to weight-loss-drug craze"
https://www.marketwatch.com/story/viking-therapeutics-stock-soars-61-premarket-after-company-reports-positive-results-in-trial-of-weight-loss-drug-50e81767

(I.e., who would have thought that the already 'high' price of VKTX would be viewed as "CHEAP"?? But it indeed is shockingly CHEAP, when compared to the only other two significant PLAYERS in entire 'Weight Loss' science field!!)

It's up 800% in 3 months this is not sustainable. Will blow threw current Cash in like a quarter and is already $1,260,000,000 billion in debt.

Are you new to biotech? VKTX will announce a stock offering in very short order, a day or two, certainly less than a week. It might be 10-15 million at $75/share for $750 million to $1.3 billion in cash so cash flow won't be an issue.

Better gain percent wise in 6 years than Apple, Nvidia, and many more in there entire life.

This was $0.08 cents now $70.00.....

This has done a bigger percent gain overall than Apple and every company I can think of in the market in a couple years. This is not sustainable in the least bit. Imho

A fade to 50 is still up 500% in 3 months

It's up 800% in 3 months this is not sustainable. Will blow threw current Cash in like a quarter and is already $1,260,000,000 billion in debt.

With a book value of $3 and change

$VKTX Debt $1,260,000,000 billion

Cash Flow Statement
Operating Cash Flow $-73.38M
Levered Free Cash Flow $-42.36M

Huge negatives

Management Effectiveness
Return on Assets -23.47%
Return on Equity -34.79%

Negative returns in large double digits

Book Value Per Share $3.48
1/20 current share price

Profitability
Profit Margin 0.00%
Operating Margin 0.00

Zero profitability

I did a small test short @ 80.47 it dropped to 66 after

WOW should have loaded the tub

Had a position since I was in my teens

Had a position since the teens
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
February 27 2024 - 07:03AM
PR Newswire (US)
Alert
Print
Share On Facebook
Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo

Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau Observed

VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 95% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate

Conference Call Scheduled for 8:00 a.m. ET Today

SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity. The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. Additionally, the study showed VK2735 treatment to be safe and well tolerated with the majority of treatment emergent adverse events (TEAEs) being categorized as mild or moderate. Based on these findings, Viking intends to meet with the FDA and discuss next steps in the development of VK2735.

HUGE day

$VKTX

Hell of an investment

Congrats

WOW $26-$36 quick

Viking Therapeutics gains amid renewed takeover speculation

12:34 PM | Viking Therapeutics, Inc. (VKTX) | By: SA Editor Joshua Fineman, SA News Editor

VKTX new 52 week high